Managing epilepsy during pregnancy requires clinicians to balance fetal safety against maternal seizure control. Recent prospective clinical findings indicate a significant link between serum micronutrient imbalances, specifically selenium and seizure recurrence, in expectant mothers. Identifying early predictive biomarkers can help clinicians anticipate clinical breakthrough and protect both mother and child throughout gestation.

Trace Element Dysregulation in Gestational Epilepsy

Trace elements serve as essential cofactors for central nervous system enzymes. Specifically, zinc, copper, and selenium regulate neurotransmission, stabilize membranes, and suppress cellular oxidative injury. However, pregnant women with epilepsy experience significant metabolic alterations that compromise trace mineral balance. Antiseizure medications often alter the intestinal absorption and hepatic clearance of essential minerals. In addition, maternal plasma volume expands rapidly during the first trimester, which dilutes circulating micronutrients. Consequently, subtle nutritional deficiencies often intensify during early gestation. Historically, clinicians have focused primarily on therapeutic drug monitoring to prevent breakthrough seizures. However, pharmacokinetic fluctuations do not explain every relapse. Emerging research indicates that profound oxidative stress contributes to neuronal hyperexcitability. In this context, excess copper promotes oxidative free radical formation, while zinc and selenium provide critical antioxidant defenses. Therefore, evaluating early trace element profiles provides valuable mechanistic insights into gestational seizure vulnerability.

First-Trimester Biomarker Profiling and Cohort Findings

To evaluate these biochemical shifts, investigators performed a prospective controlled study. The cohort included 48 pregnant women with epilepsy and 59 healthy control subjects. Importantly, all participants with epilepsy had remained completely seizure free for at least two years before conception. Clinicians collected serum samples between 6 and 12 gestational weeks, prior to any recurrence. The researchers quantified serum zinc, copper, and selenium, while also calculating the zinc-to-copper ratio. Furthermore, the statistical models adjusted for maternal age, body mass index, smoking, and gestational age. The results revealed striking physiological differences between the two groups. Compared with controls, women with epilepsy displayed 9.1% higher zinc and 56.3% higher copper levels. Conversely, their selenium concentrations were 16.8% lower, and their zinc-to-copper ratio dropped by 30.2%. These differences remained statistically significant after false discovery rate correction. Thus, pregnant women with epilepsy exhibit an altered trace mineral baseline even during prolonged clinical remission.

Examining Selenium and Seizure Recurrence During Follow-Up

During the prospective follow-up period, 20 out of 48 women experienced a seizure recurrence. This represented an unexpected relapse rate of 41.7% in previously stable patients. When analyzing clinical predictors, first-trimester selenium emerged as a primary differentiating factor. Specifically, women with seizure recurrence had significantly lower selenium concentrations than those who remained seizure free. The recurrence group had median selenium levels of 36.53 micrograms per liter, compared to 46.36 micrograms per liter in recurrence-free women. Furthermore, multivariable logistic regression adjusted for epilepsy duration and seizure type confirmed this association. Lower early selenium independently predicted subsequent seizure recurrence. In contrast, maternal age, gestational timing, and duration of epilepsy did not predict relapse. These findings demonstrate that early trace element profiling identifies clinical vulnerability before symptoms appear. Consequently, investigating selenium and seizure recurrence provides a promising prognostic avenue for clinicians managing gestational epilepsy.

Mechanisms of Oxidative Stress and Neuronal Hyperexcitability

The biological association between lower selenium and seizure recurrence involves oxidative defense pathways. Selenium is an obligatory constituent of selenoproteins, particularly glutathione peroxidase and thioredoxin reductase. Within the brain, glutathione peroxidase detoxifies harmful hydrogen peroxide and lipid hydroperoxides. As a result, adequate selenium levels protect neuronal membranes from oxidative degradation and excitotoxicity. When selenium levels drop, reactive oxygen species accumulate rapidly within cortical neurons. Furthermore, elevated serum copper promotes Fenton-type reactions, generating destructive hydroxyl radicals. This heightened oxidative stress impairs astrocytic glutamate reuptake and damages membrane transport pumps. Consequently, extracellular glutamate builds up, causing persistent neuronal depolarization. In addition, an altered zinc-to-copper ratio compromises inhibitory gamma-aminobutyric acid neurotransmission. Therefore, trace element imbalances impair neural antioxidant defenses and promote hyperexcitability, lowering the overall seizure threshold during pregnancy.

Antenatal Epilepsy Care and Implications for Indian Practice

These findings hold major clinical relevance for healthcare professionals practicing in India. Gestational epilepsy represents a prevalent clinical challenge across Indian obstetric and neurology departments. Moreover, widespread maternal micronutrient deficiencies exist throughout India due to socioeconomic factors and dietary patterns. Traditional Indian antenatal guidelines prioritize iron and folic acid supplementation, but trace elements receive limited clinical focus. Because over 40% of previously stable patients relapsed, Indian clinicians must refine risk assessment strategies. Routine therapeutic drug monitoring remains vital, yet clinicians should also consider nutritional assessments. Furthermore, vegetarian diets common in India often provide lower bioavailable selenium. Severe nausea and vomiting during the first trimester can further deplete critical micronutrient reserves. In addition, clinicians must collaborate closely across obstetrics and neurology specialties to optimize antenatal care. Recognizing trace element vulnerabilities enables clinicians to deliver comprehensive care and improve maternal-fetal outcomes.

Translational Research Frontiers and Clinical Considerations

While these prospective findings offer exciting diagnostic possibilities, clinicians must exercise caution. Currently, researchers must validate these findings in larger, ethnically diverse cohorts before modifying clinical guidelines. Future studies should determine whether specific antiseizure medications alter trace element excretion patterns differently. Furthermore, researchers must conduct clinical trials to test whether targeted selenium repletion safely prevents seizures. However, clinicians should avoid unguided selenium supplementation because excess intake causes toxic selenosis and teratogenic complications. Collaborative research will help establish precise therapeutic reference ranges for pregnant women with epilepsy. In addition, investigators should study whether neonatal cord blood reflections match maternal trace element alterations. Standardizing trace element laboratory assays across clinical settings will also improve diagnostic accuracy. Ultimately, combining biochemical profiling with standard pharmacological management could transform antenatal epilepsy care and enhance clinical outcomes.

Why are trace elements altered in pregnant women with epilepsy?

Antiseizure medications often alter hepatic metabolism, intestinal absorption, and renal clearance of essential trace minerals. Additionally, normal pregnancy triggers plasma volume expansion and placental transfer, which heightens metabolic demands on maternal reserves. Chronic epilepsy also promotes continuous oxidative stress, which progressively consumes endogenous antioxidant minerals like selenium while increasing inflammatory copper levels. Consequently, these combined physiological factors create pronounced trace element disruptions during early gestation.

Should pregnant women with epilepsy take selenium supplements to prevent seizures?

Clinicians do not currently recommend empirical selenium supplementation for pregnant women with epilepsy. Although low selenium correlates with seizure recurrence, interventional trials have not yet confirmed clinical efficacy or established safe gestational dosages. Selenium has a narrow therapeutic index, and excessive intake can trigger selenosis, maternal toxicity, and potential fetal complications. Therefore, patients should maintain a balanced diet and consult their healthcare providers before initiating any supplement.

What risks do breakthrough seizures present during pregnancy?

Seizure recurrence during pregnancy presents substantial hazards for both the mother and developing fetus. Generalized convulsive seizures can cause maternal trauma, head injuries, hypoxia, and lactic acidosis. Fetal risks include severe bradycardia, transient hypoxia, placental abruption, and spontaneous miscarriage. Furthermore, recurrent gestational seizures correlate with premature delivery and low birth weight. Therefore, multidisciplinary teams must prioritize consistent seizure control and close maternal monitoring throughout gestation.

Disclaimer: This content is for informational and educational purposes only and should not be considered as medical advice. Healthcare professionals should make diagnostic and treatment decisions based on their independent clinical judgment and the individual circumstances of each patient. Refer to the latest local and national guidelines for clinical practice.

References

1. Altınsoy H et al. First-trimester trace-element profiles in pregnant women with epilepsy: An exploratory prospective association between selenium and subsequent seizure recurrence. Int J Gynaecol Obstet. 2026 Oct 30. doi: 10.1002/ijgo.71472. PMID: 42958972.
2. Pennell PB, et al. Pregnancy Effects on Seizure Frequency: To Seize or Not to Seize. Neurochem Res. 2021;46(10):2640-2648.
3. Tomson T, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord. 2019;21(6):497-517.